Troponin T (Recombinant)

Added to your cart

Troponin T (Recombinant)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P724-3

£247.24

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Troponin T is specific to cardiac striated-muscle specific protein with a molecular weight range from 31-kDa to 36-kDa, it is the primary structural component of the Tn-Tm-actin complex. After disruption of the of the cardiomyocyte, troponin from the cytoplasmic pool is initially released, followed by a more protracted release from quantities bound to deteriorating myofilaments. In peripheral blood, cTnT begins to rise within three to four hours after the onset of myocardial injury and remains increased for 10–14 days making it an excellent biomarker of Myocardial injury.

0.1mg
P724-3

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • Trop T
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • 50mM Tris-HCI, pH 7.5 containing 0.5M NaCl, 2mM EDTA and 5mM β-mercaptoethanol
  • Presentation Matrix
  • 50mM Tris-HCI, pH 7.5 containing 0.5M NaCl, 2mM EDTA and 5mM β-mercaptoethanol
  • Purity/grade
  • >96%
  • Source
  • Expressed in E.coli
  • Molecular weight
  • ~35 kDa
  • Uniprot No.
  • P45379

Technical Documents

Certificate of Analysis (108.22KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox